Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
7/23/2025
Kelun‑Biotech Launches Phase I Trial of SKB107 in China to Tackle Bon...
7/23/2025
Qilu Initiates Global Phase III Trial of QLS31905 for Pancreatic Cance...
7/23/2025
DualityBio's DB‑1310 Earns FDA Fast‑Track for EGFR‑Mutated Lung Can...
7/23/2025
SAMR Orders Simcere to Reverse Unnotified Merger Over Competition, Pri...
7/23/2025
China-Singapore Nanovaccine Prevents Cancer Recurrence in Animals
7/23/2025
Accelerating US Oncology Drug Development Using Chinese First-in-Human...
7/22/2025
PharmaDJ's China Biopharma Tracker – June 2025 (PharmaDJ)
7/22/2025
Chimigen Raises ~CNY 170M to Advance Cancer and HepB Vaccines
7/22/2025
Innovent Secures IND for Oral GLP‑1 Agonist IBI3032 as Mazdutide Hits...
7/22/2025
Huadong Subsidiary Reports Strong Phase III Results for Roflumilast Cr...
7/22/2025
Lannacheng Secures Over CNY 300M in Series C+ to Advance Radiopharma P...
7/22/2025
Suzhou Ribo Raises Over CNY 200M to Advance siRNA Therapeutics
7/22/2025
Leads Biolabs' Hong Kong IPO Draws HK$220B in Overwhelming Demand
7/22/2025
AusperBio Cleared to Begin Phase III Trial of AHB-137 for Chronic HepB...
7/22/2025
Simcere Zaiming Secures U.S. FDA Approval for IND of FGFR2b-Targeted A...
7/22/2025
Novatim Licenses Global Rights for Dual-Target CAR-T Therapy KQ-2003 t...
7/22/2025
Cloudbreak Pharma Reports Positive Phase 2 Outcomes for CBT‑004
7/22/2025
Livzon's Dual Inhibitor LZM‑012 Positive in Global Phase III Psoriasi...
7/22/2025
CDE Issues Q&A Guidance on Pharmaceutical Similarity Studies for Biosi...
7/22/2025
CDE Solicits Comments on Proposed Labeling Update for Pediatric Use of...
7/21/2025
Novo Nordisk, Fangzhou Partner on AI-Powered Diabetes, Obesity Care
7/18/2025
Chinese Biotechs Drive Hong Kong IPO Boom in H12025
7/18/2025
China Launches 11th Round of VBP, Covering 55 Medicines with CNY 44B ...
7/18/2025
China Resources Pharma Plans CNY1B Innovation Fund to Boost Pharma Gro...
7/18/2025
CMS Launches Secondary Listing in Singapore to Fuel Regional Expansion
7/18/2025
Novartis CEO Highlights China Momentum in Q2 2025 Earnings Call
7/18/2025
China Approves Nation's First Recombinant Human Albumin Injection Deri...
7/18/2025
China Greenlights New Semaglutide Indication to Combat Kidney and Card...
7/18/2025
China Approves First Homegrown Oral Anti‑Influenza Drug by Zenshine P...
7/18/2025
Hengrui's SHR‑A1904 Emerges as Promising New Weapon Against Advanced ...
Page:
1
/
779
Total number of articles:
23345
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit